Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd specializes in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people worldwide.

msh id	COM:SANTEN
symbol	4.54K
name	Santen Pharmaceutical Co., Ltd.
homepage url	https://www.santen.com
country	JP
sector	Healthcare
industry	Drug Manufacturers - General
market	STOCKS
employee count	3.74K
crunchbase url	-
linkedin url	-
founders	-

market cap	4.25B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.22
growth cost of revenue	0.03
growth depreciation and amortization	0.01
growth ebitda	-0.76
growth ebitda ratio	-0.77
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.14
growth gross profit	0.06
growth gross profit ratio	0.01

COM:SANTEN

Santen Pharmaceutical Co., Ltd

Last Close

1,666.50

21/11 06:45

Market Cap

650.87B

Beta: -

Volume Today

1.24M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.48B
cost of revenue	1.48B
depreciation and amortization	115.52M
ebitda	345.9M
ebitda ratio	0.2
eps	0.44
eps diluted	0.44
operating expenses	774.88M
operating income	230.38M
operating income ratio	0.13

accounts receivables	-41.36M
capital expenditure	-157.85M
cash at beginning of period	532.94M
cash at end of period	371.73M
inventory	238.44M
working capital ttm	134.89B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-